Literature DB >> 1039907

Pharmacokinetics and efficacy of trimethoprim-sulfamethoxazole in the treatment of gastroenteritis in children.

M I Marks.   

Abstract

In vitro studies indicates that the constitutents of the drug combination co-trimoxazole are synergistic against Salmonella and effective against shigella isolated from children ill with gastroenteritis. The drug is well absorbed in children with gastroenteritis due to a variety of causes and is distributed, excreted and metabolized in a manner similar to that seen in normal adult volunteers. The drug is tolerated well by children with gastroenteritis even in very high dosages. Despite its in vitro and pharmacokinetic advantages, co-trimoxazole was not any more efficient than any other durg or no therapy in the treatment of salmonella gastroenteritis; it seems to have a role, however, in the treatment of typhoid fever and may be life-saving in patients infected with ampicillin- and chloramphenical-resistant strains. It is also effective in the treatment of shigella gastroenteritis and is recommended where ampicillin-resistant strains are encountered. Its potential usefulenss for the treatment of other bacterial causes of gastroenteritis in children must be evaluated by further controlled therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1039907      PMCID: PMC1956458     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  14 in total

1.  A bioavailability study on three oral preparations of the combination trimethoprim-sulfamethoxazole.

Authors:  Y Langlois; M A Gagnon; L Tétreault
Journal:  J Clin Pharmacol New Drugs       Date:  1972 May-Jun

2.  In vitro susceptibility of Shigella strains to trimethoprim and sulfamethoxazole.

Authors:  R C Rudoy; J D Nelson; K C Haltalin
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

3.  Pharmacokinetic studies of trimethoprim-sulfamethoxazole in children with gastroenteritis.

Authors:  M I Marks; M Kazemi; B Hales; A H Neims
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

4.  A controlled trial comparing sulfametboxazole-trimethoprim, ampicillin, and no therapy in the treatment of salmonella gastroenteritis in children.

Authors:  M Kazemi; T G Gumpert; M I Marks
Journal:  J Pediatr       Date:  1973-10       Impact factor: 4.406

5.  Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis. A double-blind study with ampicillin and neomycin.

Authors:  K C Haltalin; J D Nelson; L V Hinton; H T Kusmiesz; M Sladoje
Journal:  J Pediatr       Date:  1968-05       Impact factor: 4.406

6.  Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae.

Authors:  B Aserkoff; J V Bennett
Journal:  N Engl J Med       Date:  1969-09-18       Impact factor: 91.245

7.  Evaluation of trimethoprim-sulphamethoxazole compound in treatment of salmonella infections.

Authors:  A M Geddes; R Fothergill; J A Goodall; P R Dorken
Journal:  Br Med J       Date:  1971-08

8.  Evaluation of therapeutic efficacy of trimethoprim-sulphamethoxazole and chloramphenicol in enteric fever.

Authors:  S A Kamat
Journal:  Br Med J       Date:  1970-08-08

9.  Trimethoprim and sulphamethoxazole in typhoid.

Authors:  O O Akinkugbe; E A Lewis; D Montefiore; O A Okubadejo
Journal:  Br Med J       Date:  1968-09-21

10.  In vitro sensitivity of Salmonella to ten antimicrobial agents including sulfamethoxazole and trimethoprim, alone and in combination.

Authors:  M I Marks; M Kazemi; E MacKay
Journal:  Antimicrob Agents Chemother       Date:  1973-11       Impact factor: 5.191

View more
  3 in total

1.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

2.  Clinical effect and pharmacokinetics of trimethoprim-sulphadiazine in children with urinary tract infections.

Authors:  J Aarbakke; O Opshaug; A Digranes; A Høylandskjaer; G Fluge; H Fellner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole.

Authors:  W E Grose; G P Bodey; T L Loo
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.